Loading...
Loading...
Universal Health Services
- Universal Health Services, Inc. UHS's chief financial officer stated there hasn't been any notable fallout following a BuzzFeed article alleging improper clinical practices.
- Repeal and Replace isn't expected to have any downside on the company's behavioral segment.
- Repeal and Replace could spur growth in acute as states like Florida and Texas see increased funding for Medicaid expansion.
- The analysts reiterated Universal Health as the top pick in the healthcare sector.
GW Pharmaceuticals
- GW Pharmaceuticals PLC- ADR GWPH's management team expressed their confidence that an NDA filing for the middle of 2017 for its Epidiolex therapy.
- GW isn't certain if the U.S. Food and Drug Administration will hold a panel for Epidiolex but is preparing for one nevertheless.
- GW continues to look for avenues for IP protection based on either earlier preclinical work or from the ongoing EAP study.
Related Link: Why Stocks Move When Execs Cancel Presentation Appearances
Celgene
- Celgene Corporation CELG's management believes that the current drug pricing environment demonstrates the need for companies to show a strong value proposition.
- Management added that discussions with payers remain objective and constructive if a company can show the benefit to patients.
- Shifting to company specific discussions, Celgene said that Revlimid is viewed as not a single asset but part of the myeloma franchise.
- Celgene is targeting growth in every year through the 2020 to 2030 period.
- Celgene said its 2020 guidance targets have been de-risked and will update its internal model "when they have data" to change the model.
Biogen
Loading...
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorBiotechNewsEventsAnalyst RatingsMoversTrading IdeasGeneralEpidiolexhealthcare stocksLeerink Global Healthcare ConferenceMedicaidOcrevusRevlimidSell Side conferencesSpinrazaTecfideraTysabri
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in